Abstract
The ATPCI (efficAcy and safety of Trimetazidine in patients with angina pectoris treated by Percutaneous Coronary Intervention) study reported similar primary outcomes between trimetazidine and placebo groups in patients with angina who recently had a percutaneous coronary intervention, but the results of this study reconfirmed the safety of trimetazidine. The study has certain limitations in terms of design and inclusion of the target patient population. Here, we discuss these limitations and their implications on trimetazidine use in routine clinical practice.
Keywords
Trimetazidine, Percutaneous coronary intervention, Angina pectoris